S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

PRLD Prelude Therapeutics Inc

1.10

-0.09 (-7.56%)

Jan 31 2025 - Closed

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Prelude Therapeutics Charts.

Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Prelude Therapeutics Charts.

Prelude Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 7 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 3 January 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 2 January 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 11 December 2024 (2 months ago) • Edgar (US Regulatory)

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Wednesday 11 December 2024 (2 months ago) • GlobeNewswire Inc.

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Wednesday 27 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 6 November 2024 (3 months ago) • Edgar (US Regulatory)

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Wednesday 6 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 24 October 2024 (3 months ago) • Edgar (US Regulatory)

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Thursday 24 October 2024 (3 months ago) • GlobeNewswire Inc.

More Prelude Therapeutics Inc News Articles

Hurco Companies

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions